2025 Q4 -tulosraportti
Vain PDF
57 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 129 | - | - | ||
| 1 000 | - | - | ||
| 3 143 | - | - | ||
| 758 | - | - | ||
| 6 750 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenA little interesting reading from a Japanese biotech analyst summarizing the most important trends in gene therapy and cell therapy globally. Among many much larger companies, Circio is actually highlighted in the section on cardiac gene therapy as a company to watch, with a focus on the circVec data that showed significantly higher gene expression in the heart and eye compared to conventional AAV solutions. Not price-driving in itself, but it's positive to see that the technology is being noticed also outside the Norwegian stock bubble. The heart also appears to be an area that more and more people are pointing to as the next big growth area in gene therapy. https://www.linkedin.com/posts/iwao-nozawa-87b8ba5_njohzzihckpplkk-lsqmkwlkkkpp-cart-share-7470731047220195329-U8pP/?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUhttps://note.com/gay_bobcat4966/n/ncb4365b67cae
·50 min sittenThanks for the good info. Never before has a Norwegian biotechnology company been so in focus all over the world.
·2 t sittenTHEY CALLED IT TRASH. 🗑️ → 👑 For years, scientists believed that circular RNA was a mistake. A blunder. Cellular waste. Dismissed as "scrambled exons" — biological noise without purpose. Something the cell messed up by accident. The world's sharpest molecular biologists looked right at it. And dismissed it. For decades. Then everything changed. New technology revealed the truth: this "trash" was no mistake. It was stable. Preserved throughout evolution. Everywhere in the body. Some of the most robust things nature has ever created. Let that sink in. Perhaps the most valuable molecule in next-generation medicine lay right under everyone's nose — stamped as worthless — until a few saw what it actually was. It's not a biology lesson. It's a pattern. The biggest gains in history share one thing: they were laughed at first. Dismissed. Called worthless. Until consensus shifted — and then it was too late to get in cheap. The internet was a toy. Electric cars were a joke. Circular RNA was trash. Pharma is now spending billions to own exactly what they once dismissed. And you? You already have the company that built the platform around it — before the crowd turned. It's not luck. It's being early on the right side of a paradigm shift. We know what we own. ♟️🧱🍷
·2 t sittenDon't invest more than you can afford to lose. I've put a good chunk into Circio. But have already taken out 3 times as much in profit. So actually I don't give a damn if the price fluctuates between 10 and 5. Because I have absolute faith that one day it will really shoot up. And that's the day I'm waiting for. I check in and look at comments and the price approximately every 3rd day. It doesn't stress me at all if it goes down a bit.
·1 t sittenYes, then dxu plays risk-free with the profit, a good feeling that, then the price can do what it wants without stress 👍 I thought I myself had a bit high average cost on 10 sold at 12, not for the sake of profit, but it looked like it wouldn't go further after Boston, so I took a big risk to sell, and get in with a better average cost, which I have the opportunity to do now, so it was 20% in a smaller profit, and a much better average cost. 25% cheaper now, so then it will be getting back on board. But it was a big risk I took, things happen overnight, so I could be sitting here without shares with the price at 20.
·8 min sitten · MuokattuThere will be many new share issues, and then he can use the profit for that.
·2 t sitten · MuokattuWithin 2-3 weeks we are really green here - I think so then 😊 Added a bit - for 10 k today ( yes, I am a small player). Will take another 10 k if it temporarily gets crushed down to the 5-level like "eternal platform-waiters and scaremongers" love to claim 😊
·3 t sittenHow high is the probability of a licensing agreement in June-July? There is a low probability that a final, large licensing agreement will be signed and announced as early as June or July. Here are the main reasons for this: Why it takes time Early phase: Circular RNA (circRNA) is an exciting technology, but Circio is still in the preclinical phase (testing on animals and in laboratories). Complex negotiations: Large biotechnological licensing agreements usually take many months, often over a year, with thorough technical and legal review (due diligence). Summer quietness: June and especially July are holiday months in Europe, which often slows down progress in heavy business negotiations. What speaks for progress Good data: The company presented strong data at the large ASGCT conference in May, which has attracted interest from potential partners. Less haste: After the successful capital raise in June, Circio now has money for operations for a long time. They do not have to enter into a bad deal in a hurry to survive. It is more realistic to expect updates on discussions or smaller research collaborations this summer, while a large, commercial licensing agreement is likely further in the future (autumn or beyond 2027).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
57 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenA little interesting reading from a Japanese biotech analyst summarizing the most important trends in gene therapy and cell therapy globally. Among many much larger companies, Circio is actually highlighted in the section on cardiac gene therapy as a company to watch, with a focus on the circVec data that showed significantly higher gene expression in the heart and eye compared to conventional AAV solutions. Not price-driving in itself, but it's positive to see that the technology is being noticed also outside the Norwegian stock bubble. The heart also appears to be an area that more and more people are pointing to as the next big growth area in gene therapy. https://www.linkedin.com/posts/iwao-nozawa-87b8ba5_njohzzihckpplkk-lsqmkwlkkkpp-cart-share-7470731047220195329-U8pP/?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUhttps://note.com/gay_bobcat4966/n/ncb4365b67cae·50 min sittenThanks for the good info. Never before has a Norwegian biotechnology company been so in focus all over the world.
- ·2 t sittenTHEY CALLED IT TRASH. 🗑️ → 👑 For years, scientists believed that circular RNA was a mistake. A blunder. Cellular waste. Dismissed as "scrambled exons" — biological noise without purpose. Something the cell messed up by accident. The world's sharpest molecular biologists looked right at it. And dismissed it. For decades. Then everything changed. New technology revealed the truth: this "trash" was no mistake. It was stable. Preserved throughout evolution. Everywhere in the body. Some of the most robust things nature has ever created. Let that sink in. Perhaps the most valuable molecule in next-generation medicine lay right under everyone's nose — stamped as worthless — until a few saw what it actually was. It's not a biology lesson. It's a pattern. The biggest gains in history share one thing: they were laughed at first. Dismissed. Called worthless. Until consensus shifted — and then it was too late to get in cheap. The internet was a toy. Electric cars were a joke. Circular RNA was trash. Pharma is now spending billions to own exactly what they once dismissed. And you? You already have the company that built the platform around it — before the crowd turned. It's not luck. It's being early on the right side of a paradigm shift. We know what we own. ♟️🧱🍷
- ·2 t sittenDon't invest more than you can afford to lose. I've put a good chunk into Circio. But have already taken out 3 times as much in profit. So actually I don't give a damn if the price fluctuates between 10 and 5. Because I have absolute faith that one day it will really shoot up. And that's the day I'm waiting for. I check in and look at comments and the price approximately every 3rd day. It doesn't stress me at all if it goes down a bit.·1 t sittenYes, then dxu plays risk-free with the profit, a good feeling that, then the price can do what it wants without stress 👍 I thought I myself had a bit high average cost on 10 sold at 12, not for the sake of profit, but it looked like it wouldn't go further after Boston, so I took a big risk to sell, and get in with a better average cost, which I have the opportunity to do now, so it was 20% in a smaller profit, and a much better average cost. 25% cheaper now, so then it will be getting back on board. But it was a big risk I took, things happen overnight, so I could be sitting here without shares with the price at 20.·8 min sitten · MuokattuThere will be many new share issues, and then he can use the profit for that.
- ·2 t sitten · MuokattuWithin 2-3 weeks we are really green here - I think so then 😊 Added a bit - for 10 k today ( yes, I am a small player). Will take another 10 k if it temporarily gets crushed down to the 5-level like "eternal platform-waiters and scaremongers" love to claim 😊
- ·3 t sittenHow high is the probability of a licensing agreement in June-July? There is a low probability that a final, large licensing agreement will be signed and announced as early as June or July. Here are the main reasons for this: Why it takes time Early phase: Circular RNA (circRNA) is an exciting technology, but Circio is still in the preclinical phase (testing on animals and in laboratories). Complex negotiations: Large biotechnological licensing agreements usually take many months, often over a year, with thorough technical and legal review (due diligence). Summer quietness: June and especially July are holiday months in Europe, which often slows down progress in heavy business negotiations. What speaks for progress Good data: The company presented strong data at the large ASGCT conference in May, which has attracted interest from potential partners. Less haste: After the successful capital raise in June, Circio now has money for operations for a long time. They do not have to enter into a bad deal in a hurry to survive. It is more realistic to expect updates on discussions or smaller research collaborations this summer, while a large, commercial licensing agreement is likely further in the future (autumn or beyond 2027).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 129 | - | - | ||
| 1 000 | - | - | ||
| 3 143 | - | - | ||
| 758 | - | - | ||
| 6 750 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
57 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenA little interesting reading from a Japanese biotech analyst summarizing the most important trends in gene therapy and cell therapy globally. Among many much larger companies, Circio is actually highlighted in the section on cardiac gene therapy as a company to watch, with a focus on the circVec data that showed significantly higher gene expression in the heart and eye compared to conventional AAV solutions. Not price-driving in itself, but it's positive to see that the technology is being noticed also outside the Norwegian stock bubble. The heart also appears to be an area that more and more people are pointing to as the next big growth area in gene therapy. https://www.linkedin.com/posts/iwao-nozawa-87b8ba5_njohzzihckpplkk-lsqmkwlkkkpp-cart-share-7470731047220195329-U8pP/?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyUhttps://note.com/gay_bobcat4966/n/ncb4365b67cae·50 min sittenThanks for the good info. Never before has a Norwegian biotechnology company been so in focus all over the world.
- ·2 t sittenTHEY CALLED IT TRASH. 🗑️ → 👑 For years, scientists believed that circular RNA was a mistake. A blunder. Cellular waste. Dismissed as "scrambled exons" — biological noise without purpose. Something the cell messed up by accident. The world's sharpest molecular biologists looked right at it. And dismissed it. For decades. Then everything changed. New technology revealed the truth: this "trash" was no mistake. It was stable. Preserved throughout evolution. Everywhere in the body. Some of the most robust things nature has ever created. Let that sink in. Perhaps the most valuable molecule in next-generation medicine lay right under everyone's nose — stamped as worthless — until a few saw what it actually was. It's not a biology lesson. It's a pattern. The biggest gains in history share one thing: they were laughed at first. Dismissed. Called worthless. Until consensus shifted — and then it was too late to get in cheap. The internet was a toy. Electric cars were a joke. Circular RNA was trash. Pharma is now spending billions to own exactly what they once dismissed. And you? You already have the company that built the platform around it — before the crowd turned. It's not luck. It's being early on the right side of a paradigm shift. We know what we own. ♟️🧱🍷
- ·2 t sittenDon't invest more than you can afford to lose. I've put a good chunk into Circio. But have already taken out 3 times as much in profit. So actually I don't give a damn if the price fluctuates between 10 and 5. Because I have absolute faith that one day it will really shoot up. And that's the day I'm waiting for. I check in and look at comments and the price approximately every 3rd day. It doesn't stress me at all if it goes down a bit.·1 t sittenYes, then dxu plays risk-free with the profit, a good feeling that, then the price can do what it wants without stress 👍 I thought I myself had a bit high average cost on 10 sold at 12, not for the sake of profit, but it looked like it wouldn't go further after Boston, so I took a big risk to sell, and get in with a better average cost, which I have the opportunity to do now, so it was 20% in a smaller profit, and a much better average cost. 25% cheaper now, so then it will be getting back on board. But it was a big risk I took, things happen overnight, so I could be sitting here without shares with the price at 20.·8 min sitten · MuokattuThere will be many new share issues, and then he can use the profit for that.
- ·2 t sitten · MuokattuWithin 2-3 weeks we are really green here - I think so then 😊 Added a bit - for 10 k today ( yes, I am a small player). Will take another 10 k if it temporarily gets crushed down to the 5-level like "eternal platform-waiters and scaremongers" love to claim 😊
- ·3 t sittenHow high is the probability of a licensing agreement in June-July? There is a low probability that a final, large licensing agreement will be signed and announced as early as June or July. Here are the main reasons for this: Why it takes time Early phase: Circular RNA (circRNA) is an exciting technology, but Circio is still in the preclinical phase (testing on animals and in laboratories). Complex negotiations: Large biotechnological licensing agreements usually take many months, often over a year, with thorough technical and legal review (due diligence). Summer quietness: June and especially July are holiday months in Europe, which often slows down progress in heavy business negotiations. What speaks for progress Good data: The company presented strong data at the large ASGCT conference in May, which has attracted interest from potential partners. Less haste: After the successful capital raise in June, Circio now has money for operations for a long time. They do not have to enter into a bad deal in a hurry to survive. It is more realistic to expect updates on discussions or smaller research collaborations this summer, while a large, commercial licensing agreement is likely further in the future (autumn or beyond 2027).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 129 | - | - | ||
| 1 000 | - | - | ||
| 3 143 | - | - | ||
| 758 | - | - | ||
| 6 750 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt